GENFIT: The Value Is the Diagnostics Royalty, Not the $1.5 Billion Headline

GENFIT is presenting at the H.C. Wainwright global investment conference in New York this week, and on paper that is a routine item on a biotech's calendar. The reason it is worth a second look is what earned the company the slot: the stock has more than tripled in a year while the company quietly rebuilt itself from a failed blockbuster-drug story into something with a very different shape. When a beaten-down name re-rates this fast, the value question flips from "is there a floor" to "how much of the upside is already paid for." GENFIT's answer depends on telling apart the cash and royalties it already holds from a diagnostics business whose revenue it has not yet put a number on.

From failed blockbuster to royalty stream. The old GENFIT is easy to recognize. It spent years and billions of market value trying to turn its drug elafibranor into a treatment for MASH, the fatty-liver disease industry sees as a multi-billion-dollar opportunity. The drug failed its Phase 3 trial in 2020, a well-known setback. The company then re-routed it: it licensed elafibranor to Ipsen, which won U.S. accelerated approval for the drug, now called Iqirvo, in a smaller liver disease called primary biliary cholangitis (PBC). That pivot turned a failed growth story into a royalty story. Ipsen reported 2025 net sales of $208 million for Iqirvo in its first full year, crossing a $200 million threshold that triggered a $20 million milestone payment to GENFIT.

A real floor, already partly spent forward. The royalty stream now sits on a documented balance sheet. GENFIT's 2025 revenue was €65.4 million, but only €21.8 million of that was royalties; the other €43.6 million was one-time milestones that will not repeat. At the end of March 2026 it held €136.1 million in cash, and management says runway extends beyond the end of 2028. That cash is the first layer of the value argument. Against roughly a €615 million market capitalization, cash alone covers more than a fifth of the price, and the royalty engine behind it is contractually real.

The catch in that floor is that part of it has already been spent forward. In early 2025 GENFIT sold a slice of its future Iqirvo royalties to HealthCare Royalty for €130 million up front, with up to another €55 million available, in exchange for a portion of what Ipsen pays it. HealthCare Royalty's take is time- and amount-capped, and GENFIT keeps 100% of royalties only on annual net sales above €600 million. The practical effect: the company monetized a chunk of its secured drug income to fund the next chapter, so that cash is partly a prepayment of royalties GENFIT will never fully collect. The floor is real, but it is not all upside.

A $1.5 billion market GENFIT doesn't bill. The next chapter is the reason the market is paying up. GENFIT's diagnostic blood test for "at-risk" MASH, NASHnext, is commercialized through Labcorp and in July GENFIT announced Medicare reimbursement for it effective August 10, 2026, at roughly $252 per test. The company commissioned IQVIA forecasts that U.S. peak sales of products based on its NIS technology could exceed $1.5 billion by 2033, with more than 7 million tests a year, drawing on nearly 90 million Americans with MASH-related risk factors. Those are the numbers that can move a stock, and they have been doing exactly that.

But the $1.5 billion is the pool, not GENFIT's check. Labcorp develops and commercializes the test and bills the $252 Medicare rate; GENFIT is the licensor that earns a royalty on it, which the company calls its "second revenue stream" and says it will size up with guidance "in the fall." The list of TAM statistics — 90 million patients, 7 million tests, $1.5 billion of peak sales — describes the market the whole industry can serve, not what GENFIT books. What GENFIT actually keeps depends on a royalty rate and a volume ramp it has declined to quantify so far.

That gap is the investment question in one line. The market has already taken a tripled stock to a €615 million capitalization, against a cash position of €136 million, meaning roughly €480 million of the price is paying for a partially pre-funded royalty stream plus a diagnostics royalty that is still undisclosed. The conference presentation will make the story easy to find. The test that matters is different: whether the fall guidance can translate the $1.5 billion headline into a royalty GENFIT collects that is big enough to justify what has already been paid. Until that figure is on paper, the margin of safety this beaten-down biotech once had has largely been spent.